Novo Nordisk CEO tells investors to expect weight-loss drug pricing to go down before it comes back up
04.02.26 11:41 Uhr
Werbung
Werte in diesem Artikel
Indizes
PKT PKT
1.617,1 PKT -115,6 PKT -6,67%
1.322,3 PKT -67,3 PKT -4,84%
2.668,6 PKT -64,6 PKT -2,36%
5.114,5 PKT -19,0 PKT -0,37%
Recently-appointed CEO Mike Doustdar has repeatedly reset expectations since his arrival. Pricing and regulatory pressure is fierce and pessimistic revenue guidance has seen the stock clobbered 17% in Copenhagen.Weiter zum vollständigen Artikel bei MarketWatch
Quelle: MarketWatch
